Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus KANTREX.
AMIKACIN SULFATE vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic